English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 21 October 2013, 15:16 HKT/SGT
Share:
Establishment of a Chanceton Medical Committee Further Strengthen the Group's R&D Team

HONG KONG, Oct 21, 2013 - (ACN Newswire) - Chanceton Financial Group, an One-stop integrated and diversified financial services company, ("Chanceton" or the "Company"; stock code: 8020, the Company and its subsidiaries collectively called the "Group") is pleased to announce that Century Health Pharmaceutical Limited ("Century Health Pharmaceutical"), a wholly-owned subsidiary of the Company has established a medical committee (the "Medical Committee") in order to further strengthen the Group's Research & Development team. Three reputable medical experts in the PRC, namely Academician Zeng Yi ( "Academician Zeng"), Professor Li Zelin ("Professor Li") and Dr. Liu Shuwen ("Dr. Liu") respectively have been invited to the Medical Committee as the committee members.

Establishment of a Chanceton Medical Committee Further Strengthen the Group's R&D Team

Following the entering into of the Exclusive Agreement on 8 July 2013, the Board considers it is an opportunity for the Group to further bolster the collaboration with the Revenue Synthesis Group so as to leverage on the abundant resources of the Revenue Synthesis Group, including Beijing Century Health in the medical and pharmaceutical industry. In order to explore further cooperation opportunities and diversify the business risk of the business activities of the Group, the establishment of the Medical Committee is able to enhance and promote Chanceton AIDS Medication Business through the introduction of worldwide reputable AIDS medical experts by Revenue Synthesis Group and further strengthen the background of the medical and pharmaceutical team of the Group. In addition, the Medical Committee would contribute to the Group by introducing potential investors and investment opportunities which is related to the AIDS medications and therapies.

The Chairman of the Group, Ms. Ho says, "Chanceton Financial Group has great potential to be developed in the future. With the purchasing of anti-AIDS drug business, Chanceton is going to further explore business opportunities and expand in medical and pharmaceutical industries. It is my pleasure to join this big family. I believe through this project, the Group will create great potential market value in the medical circle through the bright future of anti-AIDS drug industries."

Committee member of Medical Committee, Academician Zeng Yi says, "AIDS Medication Capsule is a combination of modern scientific and technological approaches and Chinese medicine theory. 30 samples are selected after screening over 300 hundred traditional Chinese medicines, several effective herbs is selected to make a prescription named " ZL-1 capsules" . The study of which was later conducted in several foreign laboratories. Subsequent to the preclinical study, ZL-1 was approved by SFDA in 2008 for clinical trial. Since 2010, the clinical IIa stage has been completed and now IIb stage has commenced. In the future , III stage is inevitable to be completed successfully, launch to the market in order to help the patients and to obtain social and economic benefits. "


About Chanceton Financial Group Limited

The Group was founded in 1999, and the current management joined the Group in May 2008 by acquiring all shareholdings, and Chanceton Financial Group was formally established. With the support of our clients and the team's endeavor over the years, the Group was listed in the GEM board of The Stock Exchange of Hong Kong Limited on 12 October, 2011. Currently the Group has extensive network of over 200 corporates, including listed companies, institutional investors, hedge funds and professionals. Our directors and senior management have ample experience in IPO, corporate restructuring and fund raising, comprising the track records of being engaged by a number of listed companies as financial adviser and independent financial adviser. Chanceton Capital Partners Limited, a subsidiary of the Company, is one of the well-known investment banks in Hong Kong and a licensed corporation carrying Type 6 (advising on corporate finance) regulated activities under the SFO. The core business of Chanceton Capital Partners Limited is to provide financial advisory services to listed companies.

Topic: Press release summary Sectors: Daily Finance, Daily News, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Indonesia's KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge  
Dec 15, 2025 13:00 HKT/SGT
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations  
Dec 15, 2025 09:51 HKT/SGT
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership  
Monday, December 15, 2025 7:30:00 AM
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion  
Friday, December 12, 2025 10:15:00 PM
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten  
Dec 12, 2025 14:35 HKT/SGT
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition  
Friday, December 12, 2025 10:00:00 AM
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China  
Dec 11, 2025 20:00 HKT/SGT
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing  
Dec 11, 2025 18:09 HKT/SGT
Nasdaq Verafin Joins Global Anti-Scam Alliance  
Dec 11, 2025 14:21 HKT/SGT
Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards  
Dec 11, 2025 12:54 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575